Oyster Point Pharma — Technical Presentation (July 2021)
8 slides from Oyster Point Pharma's technical presentation, Jul 1, 2021
Slide 1: Varenicline Activity on SARS-CoV-2 Infection
Varenicline Activity on SARS-CoV-2 Infection July 1, 2021 Exhibit 99.1
Slide 2: Disclaimers and Forward-looking Statements
Disclaimers and Forward-looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of the “Company regarding the future of the Company’s business,
Slide 3: Varenicline Observed to Reduce SARS-CoV-2 (wildtype) Infectivity in Calu-3 Cells
Varenicline was Observed to Reduce SARS-CoV-2 (wildtype) Infectivity in Calu-3 Cells
Slide 4: SARS-CoV-2 (wildtype) Infectivity in Caco-2
Varenicline was Observed to Reduce SARS-CoV-2 (wildtype) Infectivity in Caco-2 Cells
Slide 5: SARS-CoV-2-alpha (UK Variant)
Varenicline was Observed to Reduce SARS-CoV-2-alpha (UK Variant) Infectivity in Calu-3 Cells
Slide 6: SARS-CoV-2-beta (South African Variant)
Varenicline was Observed to Reduce SARS-CoV-2-beta (South African Variant) Infectivity in Calu-3 Cells
Slide 7: Study Design for SARS-CoV-2 Challenge in Rhesus Macaques
Study Design for SARS-CoV-2 Challenge in Rhesus Macaques
Slide 8: Effect of OC-01 (varenicline) Nasal Spray on SARS-CoV-2 gRNA and sgRNA in Rhesus Macaques
Effect of OC-01 (varenicline) Nasal Spray on SARS-CoV-2 gRNA and sgRNA in Rhesus Macaques SARS-CoV-2 gRNA and sgRNA were measured by qRT-PCR in nasal swab samples taken at Day 2, Day 3, Day 5, and Day 6 of the study (equivalent to post-challenge days 1, 2, 4, and 5) for the control animals and Day 2
Oyster Point Pharma — Technical Presentation (July 2021) on 6ix